CMG48: Support for commissioning of dementia careApril 3 2013
This guidance produced by the National Institute for Health and Clinical Excellence (NICE) summarises the key commissioning issues and the resource impact that will arise from implementing improvements in the quality of care for people with dementia, in line with the statements and measures that comprise the NICE quality standards for dementia.
Download CMG48: Support for commissioning dementia care
Increased investment in the identification of people with dementia has meant that greater numbers of people are being diagnosed with dementia, often at an early stage. This is creating greater demand for services that support people to live well with dementia. There is evidence that investing in this care and support can help prevent crises, avoid unnecessary hospital admissions and reduce the avoidable use of residential care.
The Commissioning tool that accompanies this guide enables commissioners to show how well they are performing against a range of outcome measures that together demonstrate how well the whole system is working. Where data is available, the tool also demonstrates where improvements against outcome measures have prevented or reduced avoidable expenditure in the health and social care system.
This guide updates and replaces the previous NICE commissioning guides on memory assessment services (2007) and end of life care for people with dementia (2010).
This support for commissioning should be used in conjunction with the following NICE guidance and quality standards:
- NICE quality standard 1: Dementia
- NICE quality standard 30: Supporting people to live well with dementia
- NICE quality standard 13: End of life care for adults
- NICE clinical guideline 42: Dementia – supporting people with dementia and their carers in health and social care (NICE-SCIE guidance on dementia)
- NICE technology appraisal guidance 217: Alzheimer’s disease – donepezil, galantamine, rivastigmine and memantine